Riverhead Capital Management’s Haemonetics HAE Stock Holding History

Riverhead Capital Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$791K	Hold	6,271	–	–	0.03%	553
2019 Q2	$755K	Hold	6,271	–	–	0.03%	581
2019 Q1	$549K	Buy	6,271 +300	+5%	+$27.3K	0.02%	664
2018 Q4	$597K	Hold	5,971	–	–	0.03%	590
2018 Q3	$684K	Buy	5,971 +1,300	+28%	+$135K	0.02%	616
2018 Q2	$419K	Hold	4,671	–	–	0.02%	748
2018 Q1	$342K	Hold	4,671	–	–	0.01%	821
2017 Q4	$271K	Buy	4,671 +700	+18%	+$36.9K	0.01%	938
2017 Q3	$178K	Buy	3,971 +564	+17%	+$23.4K	0.01%	1033
2017 Q2	$135K	Buy	3,407 +1,507	+79%	+$61.9K	0.01%	1092
2017 Q1	$77K	Buy	1,900 +100	+6%	+$3.9K	﹤0.01%	1097
2016 Q4	$72K	Hold	1,800	–	–	﹤0.01%	1100
2016 Q3	$65K	Sell	1,800 -26,217	-94%	-$900K	﹤0.01%	1081
2016 Q2	$1.27M	Buy	28,017 +18,792	+204%	+$568K	0.04%	381
2016 Q1	$323K	Sell	9,225 -3,075	-25%	-$99.3K	﹤0.01%	1081
2015 Q4	$397K	Buy	12,300 +8,700	+242%	+$282K	0.01%	1004
2015 Q3	$116K	Buy	+3,600	New	+$135K	﹤0.01%	1008

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Riverhead Capital Management's HAE Position: Q3 2019 in Review

Riverhead Capital Management held its Haemonetics (HAE) position steady in Q3 2019 at 6,271 shares worth $791K. The position accounts for 0.03% of the portfolio, ranked #553.

Riverhead Capital Management first reported a position in HAE in Q3 2015 and has held it in 17 quarters since. The position peaked at $1.27M in Q2 2016. 275 funds tracked by Wall St. Rank hold HAE as of Q3 2019.

Riverhead Capital Management held 6,271 shares of Haemonetics worth $791K as of Q3 2019.
Riverhead Capital Management left its Haemonetics share count unchanged in Q3 2019.
Haemonetics made up 0.03% of Riverhead Capital Management's portfolio in Q3 2019, its #553 holding.
Riverhead Capital Management first reported a position in Haemonetics in Q3 2015 and has held it in 17 quarters since.
Riverhead Capital Management's Haemonetics position peaked at $1.27M in Q2 2016.
275 funds tracked by Wall St. Rank held Haemonetics as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.